LONDON, December 13 /PRNewswire/ -- The MS Society has today (13 December) welcomed an unprecedented move by the Medicines and Healthcare products Regulatory Agency (MHRA) to provide potential prescribers of the unlicensed drug Sativex more information to help them in their decision.

Sativex is an oral spray containing a cannabis extract and clinical trials are investigating its efficacy in alleviating symptoms of spasticity and pain in people with multiple sclerosis (MS).

Although currently unlicensed, it is available to people with MS on a named patient basis and around 1,200 people have so far received the drug in the UK.

LONDON, December 13 /PRNewswire/ --

- Your Chance to Hear and Question Sir Ranulph Fiennes on His Living Dangerously Lecture and Learn About the Plight of the Endangered African Lion

LONDON, December 13 /PRNewswire/ --

On Friday 18th January 2008 "An Audience with Sir Ranulph Fiennes and ALERT" will provide people with an exclusive opportunity to hear and question Sir Ranulph Fiennes on his worldwide adventures and endurance feats. As well as discussing quests such as being the first man to visit both the north and south poles by land, Fiennes will also be discussing his work as patron to the African Lion & Environmental Research Trust, ALERT.

BAAR, Switzerland, December 13 /PRNewswire/ --

- Manas Petroleum Corp. (MNAP.OB) (Manas)

"The Albanian Council of Ministers has approved Decision No. 796 regarding the approval of production sharing for exploration, development and production of hydrocarbons on onshore Albania, in Blocks A-B and D-E, between the Ministry of Economy, Trade and Energy, represented by the National Agency of Natural Resources (AKBN) and DWM Petroleum AG." DWM Petroleum AG is 100% subsidiary of Manas.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma

Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

PLYMOUTH, England, December 13 /PRNewswire/ --

- How do you Know if you Need to Call the Vet?

- Is it Urgent?

- Can it Wait Until a Normal Working Day?

Vet Help Direct is a free, interactive, online guide to help dog, horse, cat and rabbit owners decide if they need to contact the vet, and if so, how urgently. The website helps to alleviate the 'Can it wait until the next normal working day?' dilemma when faced with an ill or injured animal at night or on a bank holiday. The site is designed and run by British vets and is the first of its kind anywhere on the internet.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.